vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and MEDIFAST INC (MED). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $75.1M, roughly 1.2× MEDIFAST INC). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -36.9%). MEDIFAST INC produced more free cash flow last quarter ($-6.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -34.4%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.
IOVA vs MED — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $75.1M |
| Net Profit | — | — |
| Gross Margin | 67.4% | 69.4% |
| Operating Margin | -84.7% | -10.4% |
| Net Margin | — | — |
| Revenue YoY | 17.7% | -36.9% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-1.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $75.1M | ||
| Q3 25 | $67.5M | $89.4M | ||
| Q2 25 | $60.0M | $105.6M | ||
| Q1 25 | $49.3M | $115.7M | ||
| Q4 24 | $73.7M | $119.0M | ||
| Q3 24 | $58.6M | $140.2M | ||
| Q2 24 | $31.1M | $168.6M | ||
| Q1 24 | $715.0K | $174.7M |
| Q4 25 | — | — | ||
| Q3 25 | $-91.3M | $-2.3M | ||
| Q2 25 | $-111.7M | $2.5M | ||
| Q1 25 | $-116.2M | $-772.0K | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $1.1M | ||
| Q2 24 | $-97.1M | $-8.2M | ||
| Q1 24 | $-113.0M | $8.3M |
| Q4 25 | 67.4% | 69.4% | ||
| Q3 25 | 43.0% | 69.5% | ||
| Q2 25 | 5.5% | 72.6% | ||
| Q1 25 | -0.8% | 72.8% | ||
| Q4 24 | 68.7% | 74.1% | ||
| Q3 24 | 46.2% | 75.4% | ||
| Q2 24 | -0.8% | 73.2% | ||
| Q1 24 | — | 72.8% |
| Q4 25 | -84.7% | -10.4% | ||
| Q3 25 | -140.7% | -4.6% | ||
| Q2 25 | -189.8% | -1.0% | ||
| Q1 25 | -245.8% | -1.1% | ||
| Q4 24 | -117.5% | 0.6% | ||
| Q3 24 | -152.1% | 1.5% | ||
| Q2 24 | -327.6% | -4.7% | ||
| Q1 24 | -16464.6% | 4.5% |
| Q4 25 | — | — | ||
| Q3 25 | -135.3% | -2.5% | ||
| Q2 25 | -186.2% | 2.3% | ||
| Q1 25 | -235.5% | -0.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | 0.8% | ||
| Q2 24 | -312.2% | -4.8% | ||
| Q1 24 | -15800.8% | 4.8% |
| Q4 25 | — | $-1.64 | ||
| Q3 25 | — | $-0.21 | ||
| Q2 25 | $-0.33 | $0.22 | ||
| Q1 25 | $-0.36 | $-0.07 | ||
| Q4 24 | $-0.24 | $0.08 | ||
| Q3 24 | $-0.28 | $0.10 | ||
| Q2 24 | $-0.34 | $-0.75 | ||
| Q1 24 | $-0.42 | $0.76 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $167.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $198.9M |
| Total Assets | $913.2M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $167.3M | ||
| Q3 25 | $300.8M | $173.5M | ||
| Q2 25 | $301.2M | $162.7M | ||
| Q1 25 | $359.7M | $164.6M | ||
| Q4 24 | $323.8M | $162.3M | ||
| Q3 24 | $397.5M | $170.0M | ||
| Q2 24 | $412.5M | $163.5M | ||
| Q1 24 | $356.2M | $156.4M |
| Q4 25 | $698.6M | $198.9M | ||
| Q3 25 | $702.3M | $214.7M | ||
| Q2 25 | $698.5M | $216.0M | ||
| Q1 25 | $767.9M | $211.0M | ||
| Q4 24 | $710.4M | $210.1M | ||
| Q3 24 | $773.5M | $207.3M | ||
| Q2 24 | $768.5M | $205.3M | ||
| Q1 24 | $680.0M | $211.0M |
| Q4 25 | $913.2M | $248.0M | ||
| Q3 25 | $904.9M | $268.2M | ||
| Q2 25 | $907.4M | $269.3M | ||
| Q1 25 | $966.7M | $280.0M | ||
| Q4 24 | $910.4M | $284.2M | ||
| Q3 24 | $991.1M | $291.2M | ||
| Q2 24 | $964.3M | $293.5M | ||
| Q1 24 | $869.8M | $302.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-5.3M |
| Free Cash FlowOCF − Capex | $-61.9M | $-6.6M |
| FCF MarginFCF / Revenue | -71.3% | -8.8% |
| Capex IntensityCapex / Revenue | 10.7% | 1.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-5.3M | ||
| Q3 25 | $-78.7M | $12.1M | ||
| Q2 25 | $-67.4M | $-3.4M | ||
| Q1 25 | $-103.7M | $3.4M | ||
| Q4 24 | $-73.3M | $-4.9M | ||
| Q3 24 | $-59.0M | $9.1M | ||
| Q2 24 | $-98.4M | $13.1M | ||
| Q1 24 | $-122.3M | $7.3M |
| Q4 25 | $-61.9M | $-6.6M | ||
| Q3 25 | $-89.5M | $10.8M | ||
| Q2 25 | $-74.9M | $-4.8M | ||
| Q1 25 | $-109.9M | $1.9M | ||
| Q4 24 | $-77.5M | $-7.2M | ||
| Q3 24 | $-61.3M | $7.7M | ||
| Q2 24 | $-98.9M | $11.1M | ||
| Q1 24 | $-126.5M | $5.4M |
| Q4 25 | -71.3% | -8.8% | ||
| Q3 25 | -132.7% | 12.0% | ||
| Q2 25 | -124.9% | -4.5% | ||
| Q1 25 | -222.8% | 1.6% | ||
| Q4 24 | -105.1% | -6.1% | ||
| Q3 24 | -104.6% | 5.5% | ||
| Q2 24 | -317.9% | 6.6% | ||
| Q1 24 | -17685.3% | 3.1% |
| Q4 25 | 10.7% | 1.8% | ||
| Q3 25 | 16.1% | 1.5% | ||
| Q2 25 | 12.4% | 1.3% | ||
| Q1 25 | 12.6% | 1.3% | ||
| Q4 24 | 5.7% | 1.9% | ||
| Q3 24 | 3.9% | 1.0% | ||
| Q2 24 | 1.4% | 1.1% | ||
| Q1 24 | 583.4% | 1.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.36× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.04× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
MED
Segment breakdown not available.
